ClinicalTrials.govpublic full text
A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates
her 2 negative breast cancer, her2-negative recurrent/metastatic breast cancer, previously treated with antibody-drug conjugates, eribulin, anlotinib, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 834079
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.